Literature DB >> 24532122

Steroid use in Crohn's disease.

Stephan R Vavricka1, Alain M Schoepfer, Michael Scharl, Gerhard Rogler.   

Abstract

The incidence and prevalence of Crohn's disease are increasing, particularly in the Western world and Asia. Corticosteroids have been used for decades to treat active Crohn's disease and remain the mainstay in the management of moderate-to-severe relapses in Crohn's disease. The use of corticosteroids, despite their efficacy, may be associated with several drawbacks. This review article provides a comprehensive account of the role of corticosteroids in inducing remission in adult patients with Crohn's disease, including aspects such as approaches to corticosteroid sparing and to minimize the risk of corticosteroid dependency, as well as the role of newer corticosteroids such as budesonide in reducing systemic adverse effects.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24532122     DOI: 10.1007/s40265-014-0183-y

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  91 in total

Review 1.  Oral budesonide for induction of remission in ulcerative colitis.

Authors:  Mary E Sherlock; Cynthia H Seow; A Hillary Steinhart; Anne Marie Griffiths
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

Review 2.  The clinical pharmacology of 6-mercaptopurine.

Authors:  L Lennard
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial.

Authors:  Johanna C Escher
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-01       Impact factor: 2.566

4.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.

Authors:  A Dignass; G Van Assche; J O Lindsay; M Lémann; J Söderholm; J F Colombel; S Danese; A D'Hoore; M Gassull; F Gomollón; D W Hommes; P Michetti; C O'Morain; T Oresland; A Windsor; E F Stange; S P L Travis
Journal:  J Crohns Colitis       Date:  2010-01-15       Impact factor: 9.071

5.  Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort.

Authors:  E J Schoon; A B van Nunen; R S Wouters; R W Stockbrügger; M G Russel
Journal:  Scand J Gastroenterol Suppl       Date:  2000

6.  Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis.

Authors:  G R D'Haens; A Kovács; P Vergauwe; F Nagy; T Molnár; Y Bouhnik; W Weiss; H Brunner; A Lavergne-Slove; D Binelli; A F D Di Stefano; P Marteau
Journal:  J Crohns Colitis       Date:  2009-10-24       Impact factor: 9.071

7.  Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives.

Authors:  B Landi; T N Anh; A Cortot; J C Soule; E Rene; J P Gendre; P Bories; A See; E H Metman; C Florent
Journal:  Gastroenterology       Date:  1992-05       Impact factor: 22.682

8.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

Authors:  R Modigliani; J Y Mary; J F Simon; A Cortot; J C Soule; J P Gendre; E Rene
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

9.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

10.  A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

Authors:  O O Thomsen; A Cortot; D Jewell; J P Wright; T Winter; F T Veloso; M Vatn; T Persson; E Pettersson
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

View more
  3 in total

1.  Orally administered emu oil attenuates disease in a mouse model of Crohn's-like colitis.

Authors:  Chloe J Mitchell; Gordon S Howarth; Lauren C Chartier; Debbie Trinder; Ian C Lawrance; Li San Huang; Suzanne Mashtoub
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-09

2.  The clinical course after glucocorticoid treatment in patients with inflammatory bowel disease is linked to suppression of the hypothalamic-pituitary-adrenal axis: a retrospective observational study.

Authors:  Aghil Ibrahim; Per Dahlqvist; Tommy Olsson; David Lundgren; Mårten Werner; Ole B Suhr; Pontus Karling
Journal:  Therap Adv Gastroenterol       Date:  2017-09-21       Impact factor: 4.409

Review 3.  Osteoporosis Complications in Crohn's Disease Patients: Factors, Pathogenesis, and Treatment Outlines.

Authors:  Yaqot N Baban; Christopher M Edicheria; Joseph Joseph; Parneet Kaur; Jihan A Mostafa
Journal:  Cureus       Date:  2021-12-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.